USE OF ITOLIZUMAB IN CHRONIC PLAQUE PSORIASIS PATIENTS: CLINICAL EXPERIENCE
Anand Nott*, Vijayashree Raghavan and Nithin Sashidharan
Psoriasis is a common skin disease which carries a significant physical and psychological burden. The impact of the disease is that it not only affects the patient but, has implications on health economics. Understanding and treatment for psoriasis have moved forward greatly over the last few years. As our understanding of the immune-pathogenesis of psoriasis grows so does the opportunity for development of new therapeutic targets. We report our experience in successfully managing 5 cases of moderate to severe chronic plaque psoriasis with a novel biologic agent Itolizumab which selectively inhibits CD6 co-stimulatory pathway.
Keywords: Itolizumab, Psoriasis, Psoriasis Area and Severity Index (PASI).
[Full Text Article]